CELC logo

Celcuity LLC (CELC)

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin...

NASDAQHealthcareBiotechnologyUSA

Company Profile

Stock Code
CELC
ISIN Code
US15102K1007
Currency
US Dollar (USD)
IPO Date
2017-09-20

Contact Information

Company Address
2800 Campus Drive, Minneapolis, MN, United States, 55441
Contact Phone
(763) 392-0123
Company Website
https://www.celcuity.com
Fiscal Year End
December

Financial Highlights

Market Capitalization
$999,999.99
Gross Profit (TTM)
$0
Return on Assets (TTM)
-25.78%
EBITDA
$-999,999.99
Revenue (TTM)
$0